22308-09-4

Usage

InChI:InChI=1/C20H24O6S2/c1-16-4-8-18(9-5-16)27(21,22)25-14-20(12-3-13-20)15-26-28(23,24)19-10-6-17(2)7-11-19/h4-11H,3,12-15H2,1-2H3

Upstream product

• 10224-72-3 dimethyl cyclobutane-1,1-dicarboxylate 
• 5445-51-2 cyclobutane-1,1'-dicarboxylic acid 
• 3779-29-1 diethyl cyclobutane-1,1-dicarboxylate 
• 4415-73-0 [1-(hydroxymethyl)cyclobutyl]methanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1009566-89-5 C₁₈H₁₈Br₂O₂ 
• 1009566-90-8 C₁₈H₁₈Br₂S₂ 
• 1075-98-5 2-[1-(carboxymethyl)cyclobutyl]acetic acid 
• 64775-97-9 spiro[3.3]heptane-2,2-dicarboxylic acid 
• 28114-87-6 spiro<3.3>heptane-3-carboxylic acid 
• 64775-96-8 Spiro<3.3>heptandicarbonsaeure-2,2-diethylester 

Relevant academic research and scientific papers

TRICYCLIC COMPOUNDS AND THEIR USE

Tricyclic compounds and their use are provided. More specifically, tricyclic compounds, pharmaceutical compositions containing them, methods for preparing them, and their use in therapy are also provided.

AMINOPYRAZOLONE DERIVATIVE

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which has an excellent inhibitory action on the ATPase activity of a TIP48/TIP49 complex and as such, is useful for the treatment of tumors. [Solution] The present invention provides a compound having a structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the present specification.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

MACROCYCLIC COMPOUNDS FOR MODULATING IL-17

The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions

Spiro-Tenside und -Phospholipide: Synthese und Eigenschaften

Keywords: Micellen; Spiroverbindungen; Tenside

General Synthesis of Methyl- and Dimethyl-cyclobutanes from Simple 1,3-Diols by Phase Transfer Catalysis

A general method is described for the preparation of methyl- and dimethyl-cyclobutanes from simple 1,3-diols.The key steps of the procedure are a phase transfer catalysed ring closure and the transformation of a carboxyl group to a methyl group.Phase transfer catalysis provides good yields in the synthesis of the cyclobutane skeleton.

The Kinetics and Mechanism of Ring Opening of Radicals containing the Cyclobutylcarbinyl System

The kinetic parameters of β-fission of radicals containing the cyclobutylcarbinyl system have been determined by analysis of the mixtures obtained when suitable chloro-compounds are treated with tributylstannane.Under these conditions ring opening is irreversible and in the rigid bicyclic system (4) is under stereoelectronic control.For ring opening of cyclobutylcarbinyl radical (8) kf = 4.3 x 103 s-1 at 60 deg C, and the best values of the activation parameters appear to be ΔH(excit.) = 12.2 kcal mol-1 and ΔS(excit.) = -7.4 cal mol-1 K-1.Monocyclic systems undergo preferential fission of the more substituted βγ-bond.Methyl substituents at the α-, β-, or δ-positions have little effect but γ-substitution strongly enhances the rate of ring opening.The transition state is reactant-like and has a similar disposition of centres to that (1) for homolytic addition.